Clinical trial NCT00570336: Study of CTS-1027 in Hepatitis C Patients
Official title: A Dose Response Study of CTS-1027 in Hepatitis C Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Chronic Hepatitis C Virus Infection
Keywords: HCV
HCV treatment failure
Elevated aminotransferases
Lead sponsor: Conatus Pharmaceuticals Inc.
Sponsor class: INDUSTRY
Collaborators: name: FGK Clinical Research GmbH
First posted: 2007-12-10
Enrollment: 87
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine if CTS-1027 can lower elevated liver enzymes in patients with chronic HCV infection.

Detailed description: Randomized, placebo-controlled, double-blind, parallel group, multicenter, dose response trial utilizing four doses of CTS-1027, administered orally once daily, in outpatients with chronic hepatitis C virus (HCV) infection.

Eligibility criteria: Inclusion Criteria:

* Male or female patients of minimum adult legal age (according to local laws for signing the informed consent document), able to provide written informed consent, and understand and comply with the requirements of the trial
* A history of chronic HCV infection
* Unsuccessful HCV treatment defined as one or more of the following criteria:

  1. Failure to achieve a virologic response during previous therapy, or
  2. Failure to tolerate therapy, or
  3. Failure to maintain a sustained virologic response, or
  4. In the opinion of the Principal Investigator, the patient is not a suitable candidate for interferon based therapy
* Liver impairment, as defined by either aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) levels 1.5 - 7 x ULN on at least two occasions, seven or more days apart, during the baseline period
* Alpha-fetoprotein (AFP) \<= 50 ng/mL
* Hemoglobin \>= 10 g/dL, platelet count \>= 75 x 109/L, and white blood cell count \>= 1.5 x 109/L
* Willingness to utilize adequate contraception (if female, evidenced by being postmenopausal for at least 6 months or using contraceptive pill; for both females and males, being surgically sterile, or using two forms of barrier contraception) from screening to at least one month after the completion of the trial.

Exclusion Criteria:

* Decompensated or severe liver disease defined by one or more of the following criteria:

  1. Prior liver biopsy showing cirrhosis
  2. Prior liver biopsy showing bridging fibrosis (Metavir \>2 or Ishak \>3) more than 2 years ago in the absence of newer liver biopsy results
  3. Prothrombin time: 3 seconds \> control
  4. Total bilirubin \>= 1.5 x Upper limit of the normal range (ULN), or \> 3 x ULN for unconjugated bilirubin
  5. Serum albumin below normal limits
  6. AST or ALT \> 7 x ULN during baseline period
  7. Evidence of portal hypertension including:
* Splenomegaly or evidence of portal hypertension (i.e., enlarged portal vein and varices) on ultrasound,
* Varices in esophagogastroduodenoscopy (EGD); or
* Ascites
* Hepatocellular carcinoma (HCC) or suspicion of HCC clinically or on ultrasound (or other imaging techniques)
* Known history or presence of human immunodeficiency virus (HIV) infection
* Co-infection with hepatitis B virus (HBV)
* If female: pregnant, lactating, or positive serum or urine pregnancy test
* Last baseline AST and ALT level prior to Day 1 of \< 1.5 x ULN
* Renal impairment (creatinine \> 1.5 x ULN) or hepatorenal syndrome
* Pancreatitis
* Hospitalization for liver disease within 60 days of screening
* Use of concomitant or prior drug therapy for HCV at screening, including the use of:

  1. drugs with presumed anti-HCV activity in the prior three months
  2. corticosteroids in the past 30 days
  3. potentially hepatotoxic drugs in the past 30 days (including alpha methyl-dopa, sodium valproic acid, isoniazide, or nitrofurantoin)
* Use of illicit or drugs of abuse in the prior three months (allowed if medically prescribed or indicated)
* History of alcohol abuse within the past year
* History or presence of clinically concerning cardiac arrhythmias or prolongation of pre-dose QT or QTc interval of \> 450 milliseconds
* Other concomitant disease or condition likely to significantly decrease life expectancy (e.g., moderate to severe congestive heart failure) or any malignancy other than curatively treated skin cancer (basal cell or squamous cell carcinomas), unless adequately treated or in complete remission for ten or more years
* Any patient who has received any investigational drug or device within 30 days of dosing, or who is scheduled to receive another investigational drug or device during the course of this trial.

Primary outcomes:
measure: Number of adverse events at each dose level
timeFrame: 4 to 24 weeks
measure: Alanine aminotransferase (ALT) and Aspartate aminotransferase (AST) levels at each dose
timeFrame: 4-24 Weeks
Secondary outcomes:
measure: Peak and trough levels of CTS-1027 in plasma
timeFrame: 4 to 24 weeks
Other outcomes:
Locations:
city: Birmingham
country: United States
facility: University of Alabama at Birmingham
state: Alabama
city: La Jolla
country: United States
facility: Scripps Clinic
state: California
city: San Diego
country: United States
facility: Kaiser Permanente
state: California
city: San Francisco
country: United States
facility: California Pacific Medical Center
state: California
city: Aurora
country: United States
facility: University of Colorado Denver
state: Colorado
city: Miami
country: United States
facility: University of Miami
state: Florida
city: Atlanta
country: United States
facility: Digestive Healthcare of Georgia
state: Georgia
city: New Orleans
country: United States
facility: Tulane University Health Sciences Center
state: Louisiana
city: Boston
country: United States
facility: Beth Israel Deaconess Medical Center
state: Massachusetts
city: West Bloomfield
country: United States
facility: Henry Ford Health System
state: Michigan
city: Rochester
country: United States
facility: Mayo Clinic
state: Minnesota
city: Bronx
country: United States
facility: Bronx VA Medical Center
state: New York
city: New York
country: United States
facility: Mt. Sinai School of Medicine
state: New York
city: Durham
country: United States
facility: Duke University Medical Center
state: North Carolina
city: Cincinnati
country: United States
facility: Consultants of Clinical Research
state: Ohio
city: Cleveland
country: United States
facility: Cleveland Clinic
state: Ohio
city: Houston
country: United States
facility: Advanced Liver Therapies - Baylor College of Medicine
state: Texas
city: Houston
country: United States
facility: VAMC - Baylor College of Medicine
state: Texas
city: Richmond
country: United States
facility: McGuire Hospital DVAMC
state: Virginia
Study officials:
affiliation: Conatus Pharmaceuticals Inc.
name: William Frank, MD
role: STUDY_DIRECTOR
References: